U.S. President Donald Trump is anticipated to urge the U.S. government to loosen federal restrictions on marijuana in a major way, cutting oversight of the plant and its derivatives to the same level as some ordinary prescription painkillers and other medicines, the Washington Post’s Jacob Bogage and Dan Diamond report, citing six people familiar with the discussions. The president has discussed the plan with House Speaker Mike Johnson and is expected to aim to broaden access to the drug through an upcoming executive order that directs federal agencies to pursue reclassification, the authors note. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN) and Trulieve Cannabis (TCNNF).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACB:
- Aurora Cannabis announces launch of Black Jelly in Poland
- Aurora Cannabis enters distribution partnership with Leafio Australia
- TLRY, CGC, CRON: Cannabis Stocks Jump as U.S. Medicare Considers Coverage
- Aurora Cannabis Reports Strong Q2 2026 Results
- Aurora Cannabis Earnings Call: Record Growth Amid Challenges